Compare Citius Pharmaceuticals Inc (CTXR) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Sony Group Corp trades at $20.8 (market cap $122.79B). The key difference: Sony Group Corp is far larger — about 8387.3× Citius Pharmaceuticals Inc's market cap, and Sony Group Corp pays a 0.76% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SONY | |
|---|---|---|
Market Cap | $14.64M | $122.79B |
Sector | Health | Technology |
52-Week High | $1.82 | $30.26 |
52-Week Low | $0.53 | $19.32 |
Enterprise Value | $10.86M | $119.28B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Sony trades at $20.68, down 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong operating cash flow of $2.32 trillion for 2025 and maintains solid valuation metrics including a P/E of 19.51. Recent news highlights Sony's strategic shift to digital-only PlayStation games by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook remains mixed with analyst consensus strongly bullish (69% buy ratings) but near-term earnings volatility. Key opportunities include digital transformation and financial services expansion, while risks involve execution of digital strategy and projected net income decline to -$326.9 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
